A new clinical published in Arthritis & Rheumatology reveals that nintedanib, a medication that helps prevent changes to lung tissue, may help patients with fibrosing autoimmune disease-related interstitial lung diseases (ILDs), which are a common manifestation of systemic autoimmune diseases such as rheumatoid arthritis.
In the trial, 170 patients with autoimmune disease-related ILDs were randomized to nintedanib or placebo. Investigators assessed patients’ forced vital capacity (FVC), or the maximum amount of air one can forcibly exhale from the lungs after fully inhaling. (FVC is a predictor of mortality in patients with autoimmune disease-associated ILDs.)
The rate of decline in FVC over one year was -75.9 mL/year with nintedanib versus -178.6 mL/year with placebo.
“Until now, therapies that can significantly reduce the rate of decline in lung function in connective tissue disease–related ILDs characterized by progressive fibrosis have been lacking. We now have a therapeutic approach that offers a strategy for reducing the morbidity associated with these diseases,” said lead author Eric L. Matteson, MD, MPH, of the Mayo Clinic College of Medicine and Science.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1002/art.42075
About Journal
Arthritis & Rheumatology, an official journal of the American College of Rheumatology, is a peer-reviewed publication for scientists and clinicians interested in the natural history, pathophysiology, treatment, and outcome of the rheumatic diseases. The journal publishes the highest quality basic and clinical research related to the rheumatic diseases, encompassing a wide range of areas of investigative activity. In addition, Arthritis & Rheumatology publishes review articles, editorials, and other educational material intended for both researchers and clinicians.
About Wiley
Wiley is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world’s knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us at Wiley.com, like us on Facebook and follow us on Twitter and LinkedIn.